You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 14, 2025

Details for Patent: 10,201,584


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,201,584 protect, and when does it expire?

Patent 10,201,584 protects VIEKIRA XR and is included in one NDA.

Summary for Patent: 10,201,584
Title:Compositions and methods for treating HCV
Abstract: This disclosure is directed to pharmaceutical compositions that comprise two or more therapeutic agents that, inter alia, are useful for inhibiting hepatitis C virus (HCV) and methods for inhibiting HCV by co-administering two or more anti-HCV therapeutic agents.
Inventor(s): Collins; Christine A. (Skokie, IL), Cohen; Daniel E. (Highland Park, IL), Koev; Gennadiy (Libertyville, IL), Krishnan; Preethi (Gurnee, IL), Pilot-Matias; Tami J. (Green Oaks, IL)
Assignee: ABBVIE INC. (North Chicago, IL)
Application Number:14/247,975
Patent Claim Types:
see list of patent claims
Use; Composition;
Patent landscape, scope, and claims:

Detailed Analysis of the Scope and Claims of United States Patent 10,201,584

Introduction

Understanding the scope and claims of a patent is crucial for navigating the complex landscape of intellectual property. This analysis will delve into the specifics of United States Patent 10,201,584, focusing on its claims, scope, and the broader patent landscape.

Overview of the Patent

United States Patent 10,201,584 is directed to pharmaceutical compositions that comprise two or more therapeutic agents, particularly useful for inhibiting hepatitis C virus (HCV)[5].

Patent Claims

The claims of a patent define the scope of the invention and are critical for determining what is protected under the patent.

Independent Claims

Independent claims are those that stand alone and do not depend on other claims. For U.S. Patent 10,201,584, the independent claims typically outline the core invention, such as the specific pharmaceutical compositions and their therapeutic uses.

Dependent Claims

Dependent claims build upon the independent claims and provide additional details or limitations. These claims often narrow down the scope of the invention by adding specific features or conditions.

Scope of the Patent

The scope of a patent is determined by the language of the claims and is a key factor in patent litigation and licensing.

Claim Language and Scope

Research has shown that the length and count of independent claims can be metrics for measuring patent scope. Patents with narrower claims at publication tend to have a higher probability of grant and a shorter examination process[3].

For U.S. Patent 10,201,584, the scope would be defined by the specific therapeutic agents, their combinations, and the methods of use for treating HCV. The broader the claims, the more potential applications and uses are covered, but this also increases the risk of challenges based on prior art or obviousness.

Patent Examination Process

The examination process plays a significant role in shaping the final scope of a patent.

Narrowing of Claims

During the examination process, patent claims often undergo revisions to narrow their scope. This is done to ensure that the claims are novel, non-obvious, and fully described in the specification. Studies have shown that the examination process tends to narrow the scope of patent claims, particularly in terms of claim length and count[3].

Patent Landscape

Understanding the broader patent landscape is essential for assessing the value and potential challenges of a patent.

Related Patents and Prior Art

Using tools like the USPTO's Patent Public Search, Global Dossier, and international databases such as PATENTSCOPE, one can identify related patents and prior art that may impact the validity or scope of U.S. Patent 10,201,584[1][4].

International Patent Offices

Given the global nature of pharmaceutical research, it is crucial to search international patent offices to see if similar inventions have been patented abroad. Databases like esp@cenet (European Patent Office), JPO (Japan Patent Office), and WIPO's PATENTSCOPE provide access to international patent applications and granted patents[1].

Challenges and Validity

Patents can face various challenges, including obviousness-type double patenting and lack of written description.

Obviousness-Type Double Patenting

This doctrine can invalidate claims if they are not patentably distinct from earlier-filed or earlier-issued patents. For example, in the case of Allergan USA, Inc. v. MSN Laboratories Private Ltd., the court found that a patent claim was invalid due to obviousness-type double patenting over later-filed but earlier-issued patents[2].

Written Description

Claims must be fully supported by the written description in the patent specification. If the claims are too broad or not adequately described, they may be challenged for lack of written description[2].

Key Takeaways

  • Claim Language: The scope of U.S. Patent 10,201,584 is defined by its claim language, with independent claims outlining the core invention and dependent claims providing additional details.
  • Examination Process: The patent examination process can significantly narrow the scope of claims to ensure novelty, non-obviousness, and full description.
  • Patent Landscape: Understanding related patents and prior art, both domestically and internationally, is crucial for assessing the patent's validity and value.
  • Challenges: Patents can face challenges such as obviousness-type double patenting and lack of written description, which can impact their validity.

FAQs

What is the primary focus of U.S. Patent 10,201,584?

U.S. Patent 10,201,584 is focused on pharmaceutical compositions that comprise two or more therapeutic agents useful for inhibiting hepatitis C virus (HCV).

How do independent and dependent claims differ?

Independent claims stand alone and define the core invention, while dependent claims build upon the independent claims and provide additional details or limitations.

What role does the patent examination process play in shaping the scope of a patent?

The patent examination process often narrows the scope of claims to ensure they are novel, non-obvious, and fully described in the specification.

Why is it important to search international patent offices?

Searching international patent offices helps identify related patents and prior art that may impact the validity or scope of a patent, given the global nature of research and development.

What is obviousness-type double patenting?

Obviousness-type double patenting is a doctrine that can invalidate patent claims if they are not patentably distinct from earlier-filed or earlier-issued patents.

Sources

  1. USPTO: Search for patents - USPTO.
  2. CAFC: ALLERGAN USA, INC. v. MSN LABORATORIES PRIVATE LTD.
  3. SSRN: Patent Claims and Patent Scope.
  4. Clemson University: Research and Course Guides: Patent Searching, Advanced: Overview.
  5. DrugPatentWatch: Drugs covered by patent 10,201,584. Claims, international patent ...

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 10,201,584

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie VIEKIRA XR dasabuvir sodium; ombitasvir; paritaprevir; ritonavir TABLET, EXTENDED RELEASE;ORAL 208624-001 Jul 22, 2016 DISCN Yes No ⤷  Try for Free ⤷  Try for Free TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.